BDBM50507816 Bms-986165::Deucravacitinib

SMILES [2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC

InChI Key InChIKey=BZZKEPGENYLQSC-FIBGUPNXSA-N

Data  3 KI  44 IC50  4 Kd  2 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 53 hits for monomerid = 50507816   

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 3nMAssay Description:Inhibition of TYK2 dependent IFNalpha-stimulated STAT3 phosphorylation in human PBMCMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2024
Entry Details
PubMed
TargetCytochrome P450 2C9(Human)
TBA

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 4.00E+4nMAssay Description:Inhibition of CYP2C9 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataEC50:  13nMAssay Description:Inhibition of TYK2 in human whole blood assessed as reduction in IFN-alpha stimulated TYK2 phosphorylationMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2021
Entry Details Article
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of TYK2 JH2 domain (unknown origin) by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2022
Entry Details Article
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 5.30nMAssay Description:Inhibition of TYK2 in IFN-alpha stimulated human Kit225 T cells by luciferase reporter gene assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2022
Entry Details Article
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 18nMAssay Description:Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylationMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2022
Entry Details Article
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 3.20nMAssay Description:Inhibition of TYK2 in human Jurkat cells assessed as reduction in IFNalpha induced STAT3 phosphorylation incubated for 24 hrs by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/22/2023
Entry Details
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of TYK2 JH2 domain (unknown origin) by HTRF based binding assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2024
Entry Details
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of JAK1 JH1 domain (unknown origin) by HTRF based binding assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2024
Entry Details
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of JAK2 JH1 domain (unknown origin) by HTRF based binding assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2024
Entry Details
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of JAK3 JH1 domain (unknown origin) by HTRF based binding assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2024
Entry Details
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) by HTRF based binding assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2024
Entry Details
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataKd:  0.330nMAssay Description:Binding affinity to human JAK1 JH2 domain assessed as dissociation constantMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2024
Entry Details
PubMed
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 5nMAssay Description:Inhibition of JAK1/TYK2 in human Kit225 T cells assessed as inhibition of STAT phosphorylation by luciferase reporter assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of JAK2 dependent TPO stimulated STAT5 phosphorylation in human TF-1 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2024
Entry Details
PubMed
TargetPlatelet-derived growth factor receptor alpha/beta(Mouse)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 592nMAssay Description:Inhibition of JAK1/JAK3 in human PBMC assessed as inhibition of IL2-stimulated phosphorylation of STAT5More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2024
Entry Details
PubMed
TargetPlatelet-derived growth factor receptor alpha/beta(Mouse)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 100nMAssay Description:Inhibition of JAK1/JAK2 in CD3+ human PBMC assessed as inhibition of IL6-stimulated phosphorylation of STAT3More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2024
Entry Details
PubMed
TargetPlatelet-derived growth factor receptor alpha/beta(Mouse)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 158nMAssay Description:Inhibition of JAK1/JAK2 in CD3+ human HT-29 cells assessed as inhibition of IL22-stimulated phosphorylation of STAT3More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2024
Entry Details
PubMed
TargetSignal transducer and activator of transcription 3(Human)
Yale University

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 89nMAssay Description:Inhibition of IL-23 induced STAT3 phosphorylation in human KIT225 cells by AlphaLISA assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2024
Entry Details
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataKd:  0.00800nMAssay Description:Binding affinity to TYK2 JH2 (unknown origin) assessed as dissociation constantMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2024
Entry Details
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataKd:  0.230nMAssay Description:Binding affinity to JAK1 JH2 (unknown origin) assessed as dissociation constantMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2024
Entry Details
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 5nMAssay Description:Inhibition of JAK1 signaling pathway in human PBMC cells assessed as reduction of IL-2 induced STAT5 phosphorylationMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2024
Entry Details
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 3nMAssay Description:Inhibition of JAK3 signaling pathway in human PBMC cells assessed as reduction of IL-2 induced STAT5 phosphorylationMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2024
Entry Details
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataKd:  10nMAssay Description:Binding affinity to JAK2 JH2 (unknown origin) assessed as dissociation constantMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2024
Entry Details
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of human recombinant C-terminal Histidine tagged TYK2 JH2 (564 to 876 residues) expressed in Sf9 cells by chromatography methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2024
Entry Details
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 4.60nMAssay Description:Inhibition of TYK2 dependent IFNalpha-stimulated STAT3 phosphorylation in human Jurkat cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/22/2024
Entry Details
PubMed
TargetCytochrome P450 2C19(Human)
TBA

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 4.00E+4nMAssay Description:Inhibition of CYP2C19 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK1/JAK2(Human)
TBA

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 609nMAssay Description:Inhibition of JAK1/JAK2 in in human whole blood assessed as decrease in IL6-induced STAT3 phosphorylation in CD3+ T cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
TBA

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 4.00E+4nMAssay Description:Inhibition of CYP2D6 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 0.200nMAssay Description:Allosteric inhibition of fluorescein labeled probe binding to His-tagged recombinant human TYK2 pseudokinase JH2 domain (575-869 residues) incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 13nMAssay Description:Inhibition of TYK2 in human whole blood assessed as decrease in IFNalpha-induced STAT5 phosphorylation preincubated for 1 hr followed by stimulation ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 8.00E+4nMAssay Description:Inhibition of human ERG by in vitro patch clamp methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 9nMAssay Description:Inhibition of TYK2 in human PBMC assessed as decrease in IL23-induced STAT3 phosphorylation in CD161+/CD3+ T cells preincubated for 1 hr followed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of JAK2 in human TF1 cells assessed as decrease in EPO-induced STAT5A phosphorylation incubated for 10 mins by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 615nMAssay Description:Inhibition of JAK1 in human PBMC assessed as decrease in IL6-induced STAT5 phosphorylation in CD3+ T cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 2.09E+3nMAssay Description:Inhibition of JAK1 in human PBMC assessed as decrease in IL13-induced STAT6 phosphorylation in mononuclear cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of JAK2 in human whole blood assessed as decrease in TPO-induced STAT5 phosphorylation in plateletsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 193nMAssay Description:Inhibition of BMPR2 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 100nMAssay Description:Inhibition of TYK2 in mouse whole blood assessed as decrease in IFNalpha-induced STAT1 phosphorylation preincubated for 1 hr followed by stimulation ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetCytochrome P450 1A2(Human)
TBA

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 4.00E+4nMAssay Description:Inhibition of CYP1A2 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
TBA

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 4.00E+4nMAssay Description:Inhibition of CYP3A4 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of fluorescein labeled probe binding to human recombinant JAK1 JH1 domain incubated for 1 hr by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of fluorescein labeled probe binding to human recombinant TYK2 JH1 domain incubated for 1 hr by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 1nMAssay Description:Inhibition of fluorescein labeled probe binding to human recombinant JAK1 JH2 incubated for 1 hr by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetJAK3/JAK1(Human)
TBA

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 592nMAssay Description:Inhibition of JAK1/JAK3 in human PBMC assessed as decrease in IL2-induced STAT5 phosphorylation in CD3+ T cells preincubated for 1 hr followed by sti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetJAK3/JAK1(Human)
TBA

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 1.90E+3nMAssay Description:Inhibition of JAK1/JAK3 in in human whole blood assessed as decrease in IL2-induced STAT5 phosphorylation in CD3+ T cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
TBA

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataEC50: >4.00E+4nMAssay Description:Induction of CYP3A4 (unknown origin) by PXR-transactivation assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of fluorescein labeled probe binding to human recombinant JAK2 JH1 domain incubated for 1 hr by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 2nMAssay Description:Inhibition of TYK2 in human PBMC assessed as decrease in IFNalpha-induced STAT5 phosphorylation in CD3+ T cells preincubated for 1 hr followed by sti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50507816(Bms-986165 | Deucravacitinib)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of fluorescein labeled probe binding to human recombinant JAK3 JH1 domain incubated for 1 hr by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
Displayed 1 to 50 (of 53 total ) | Next | Last >>